Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Maytansinoid immunoconjugate IMGN901 is cytotoxic in a three-dimensional culture model of multiple myeloma.

Nierste BA, Gunn EJ, Whiteman KR, Lutz RJ, Kirshner J.

Am J Blood Res. 2016 May 18;6(1):6-18. eCollection 2016.

2.

IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.

Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J, Goldmacher VS, Chittenden T, Lambert JM.

Mol Cancer Ther. 2015 Jul;14(7):1605-13. doi: 10.1158/1535-7163.MCT-14-1095. Epub 2015 Apr 22.

3.

Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.

Hong EE, Erickson H, Lutz RJ, Whiteman KR, Jones G, Kovtun Y, Blanc V, Lambert JM.

Mol Pharm. 2015 Jun 1;12(6):1703-16. doi: 10.1021/acs.molpharmaceut.5b00175. Epub 2015 Apr 27.

PMID:
25856201
4.

Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.

Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, Zukerberg L, Lambert JM, Lutz RJ.

MAbs. 2014 Mar-Apr;6(2):556-66. doi: 10.4161/mabs.27756. Epub 2014 Jan 8.

5.

A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.

Deckert J, Park PU, Chicklas S, Yi Y, Li M, Lai KC, Mayo MF, Carrigan CN, Erickson HK, Pinkas J, Lutz RJ, Chittenden T, Lambert JM.

Blood. 2013 Nov 14;122(20):3500-10. doi: 10.1182/blood-2013-05-505685. Epub 2013 Sep 3.

PMID:
24002446
6.

SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.

Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, Lambert JM.

Clin Cancer Res. 2011 Oct 15;17(20):6448-58. doi: 10.1158/1078-0432.CCR-11-0485. Review.

7.

Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage.

Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, Payne G, Steeves R, Whiteman KR, Widdison W, Xie H, Singh R, Chari RV, Lambert JM, Lutz RJ.

Bioconjug Chem. 2011 Apr 20;22(4):717-27. doi: 10.1021/bc100480a. Epub 2011 Mar 22.

PMID:
21425776
8.

Antibody-maytansinoid conjugates designed to bypass multidrug resistance.

Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, Ab O, Lai KC, Widdison WC, Kellogg B, Johnson H, Pinkas J, Lutz RJ, Singh R, Goldmacher VS, Chari RV.

Cancer Res. 2010 Mar 15;70(6):2528-37. doi: 10.1158/0008-5472.CAN-09-3546. Epub 2010 Mar 2.

9.

Sustained subconjunctival protein delivery using a thermosetting gel delivery system.

Rieke ER, Amaral J, Becerra SP, Lutz RJ.

J Ocul Pharmacol Ther. 2010 Feb;26(1):55-64. doi: 10.1089/jop.2009.0059.

10.

Antibody-maytansinoid conjugates for the treatment of myeloma.

Lutz RJ, Whiteman KR.

MAbs. 2009 Nov-Dec;1(6):548-51. Epub 2009 Nov 9. Review.

11.

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.

Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, Perrone G, Tai YT, Cirstea D, Raje NS, Uherek C, Dälken B, Aigner S, Osterroth F, Munshi N, Richardson P, Anderson KC.

Clin Cancer Res. 2009 Jun 15;15(12):4028-37. doi: 10.1158/1078-0432.CCR-08-2867. Epub 2009 Jun 9.

12.

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX.

Cancer Res. 2008 Nov 15;68(22):9280-90. doi: 10.1158/0008-5472.CAN-08-1776.

13.

Transport barriers in transscleral drug delivery for retinal diseases.

Kim SH, Lutz RJ, Wang NS, Robinson MR.

Ophthalmic Res. 2007;39(5):244-54. Epub 2007 Sep 12. Review.

PMID:
17851264
14.

Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging.

Kim SH, Csaky KG, Wang NS, Lutz RJ.

Pharm Res. 2008 Mar;25(3):512-20. Epub 2007 Aug 3.

PMID:
17674155
15.

Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models.

Chen Q, Millar HJ, McCabe FL, Manning CD, Steeves R, Lai K, Kellogg B, Lutz RJ, Trikha M, Nakada MT, Anderson GM.

Clin Cancer Res. 2007 Jun 15;13(12):3689-95.

16.

Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging.

Kim SH, Galbán CJ, Lutz RJ, Dedrick RL, Csaky KG, Lizak MJ, Wang NS, Tansey G, Robinson MR.

Invest Ophthalmol Vis Sci. 2007 Feb;48(2):808-14.

PMID:
17251481
17.

Semisynthetic maytansine analogues for the targeted treatment of cancer.

Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, Goldmacher VS, Xie H, Steeves RM, Lutz RJ, Zhao R, Wang L, Blättler WA, Chari RV.

J Med Chem. 2006 Jul 13;49(14):4392-408.

PMID:
16821799
18.

Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration.

Kim H, Csaky KG, Gravlin L, Yuan P, Lutz RJ, Bungay PM, Tansey G, DE Monasterio F, Potti GK, Grimes G, Robinson MR.

Retina. 2006 May-Jun;26(5):523-30.

PMID:
16770258
19.

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blättler WA.

Cancer Res. 2006 Apr 15;66(8):4426-33.

20.

The pharmacokinetics of rituximab following an intravitreal injection.

Kim H, Csaky KG, Chan CC, Bungay PM, Lutz RJ, Dedrick RL, Yuan P, Rosenberg J, Grillo-Lopez AJ, Wilson WH, Robinson MR.

Exp Eye Res. 2006 May;82(5):760-6. Epub 2005 Nov 11.

PMID:
16289160
21.

A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide.

Robinson MR, Lee SS, Kim H, Kim S, Lutz RJ, Galban C, Bungay PM, Yuan P, Wang NS, Kim J, Csaky KG.

Exp Eye Res. 2006 Mar;82(3):479-87. Epub 2005 Sep 15.

PMID:
16168412
22.

Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant.

Park J, Bungay PM, Lutz RJ, Augsburger JJ, Millard RW, Sinha Roy A, Banerjee RK.

J Control Release. 2005 Jul 20;105(3):279-95.

PMID:
15896868
23.

Study of ocular transport of drugs released from an intravitreal implant using magnetic resonance imaging.

Kim H, Lizak MJ, Tansey G, Csaky KG, Robinson MR, Yuan P, Wang NS, Lutz RJ.

Ann Biomed Eng. 2005 Feb;33(2):150-64.

PMID:
15771269
24.

Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease.

Kim H, Csaky KG, Gilger BC, Dunn JP, Lee SS, Tremblay M, de Monasterio F, Tansey G, Yuan P, Bungay PM, Lutz RJ, Robinson MR.

Invest Ophthalmol Vis Sci. 2005 Feb;46(2):655-62.

PMID:
15671296
25.

Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging.

Kim H, Robinson MR, Lizak MJ, Tansey G, Lutz RJ, Yuan P, Wang NS, Csaky KG.

Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2722-31.

PMID:
15277497
26.

Estimation of the differential pressure at renal artery stenoses.

Yim PJ, Cebral JR, Weaver A, Lutz RJ, Soto O, Vasbinder GB, Ho VB, Choyke PL.

Magn Reson Med. 2004 May;51(5):969-77.

27.

Mixing during intravertebral arterial infusions in an in vitro model.

Lutz RJ, Warren K, Balis F, Patronas N, Dedrick RL.

J Neurooncol. 2002 Jun;58(2):95-106.

PMID:
12164691
28.

Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate.

Ross S, Spencer SD, Holcomb I, Tan C, Hongo J, Devaux B, Rangell L, Keller GA, Schow P, Steeves RM, Lutz RJ, Frantz G, Hillan K, Peale F, Tobin P, Eberhard D, Rubin MA, Lasky LA, Koeppen H.

Cancer Res. 2002 May 1;62(9):2546-53.

29.
30.

Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals.

Han J, Flemington C, Houghton AB, Gu Z, Zambetti GP, Lutz RJ, Zhu L, Chittenden T.

Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11318-23.

31.

Simulated lipoprotein transport in the wall of branched arteries.

Darbeau MZ, Lutz RJ, Collins WE.

ASAIO J. 2000 Nov-Dec;46(6):669-78.

PMID:
11110263
32.

Manometric changes during retrograde biliary infusion in mice.

Wiener SM, Hoyt RF Jr, Deleonardis JR, Clevenger RR, Jeffries KR, Nagashima K, Mandel M, Owens J, Eckhaus M, Lutz RJ, Safer B.

Am J Physiol Gastrointest Liver Physiol. 2000 Jul;279(1):G49-66.

33.

Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155.

Zhou XM, Liu Y, Payne G, Lutz RJ, Chittenden T.

J Biol Chem. 2000 Aug 11;275(32):25046-51.

34.
35.

A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2.

Goldmacher VS, Bartle LM, Skaletskaya A, Dionne CA, Kedersha NL, Vater CA, Han JW, Lutz RJ, Watanabe S, Cahir McFarland ED, Kieff ED, Mocarski ES, Chittenden T.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12536-41.

36.
37.

Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria.

Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, Matsuda H, Tsujimoto Y.

Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14681-6.

38.

Quantification and pharmacokinetics of blood-brain barrier disruption in humans.

Zünkeler B, Carson RE, Olson J, Blasberg RG, DeVroom H, Lutz RJ, Saris SC, Wright DC, Kammerer W, Patronas NJ, Dedrick RL, Herscovitch P, Oldfield EH.

J Neurosurg. 1996 Dec;85(6):1056-65.

PMID:
8929495
39.

A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions.

Chittenden T, Flemington C, Houghton AB, Ebb RG, Gallo GJ, Elangovan B, Chinnadurai G, Lutz RJ.

EMBO J. 1995 Nov 15;14(22):5589-96.

40.

Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins.

Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ, Ebb RG, Subramanian T, Chittenden T, Lutz RJ, et al.

Oncogene. 1995 Nov 2;11(9):1921-8.

PMID:
7478623
41.

An in vitro flow model to study streaming during pelvic intra-arterial drug infusions.

Lutz RJ, Epstein AH, Cook JA, Dedrick RL.

Gynecol Oncol. 1995 Nov;59(2):288-96.

PMID:
7590489
42.

Induction of apoptosis by the Bcl-2 homologue Bak.

Chittenden T, Harrington EA, O'Connor R, Flemington C, Lutz RJ, Evan GI, Guild BC.

Nature. 1995 Apr 20;374(6524):733-6.

PMID:
7715730
43.

Different analogues of farnesyl pyrophosphate inhibit squalene synthase and protein:farnesyltransferase to different extents.

Cohen LH, Valentijn AR, Roodenburg L, Van Leeuwen RE, Huisman RH, Lutz RJ, Van der Marel GA, Van Boom JH.

Biochem Pharmacol. 1995 Mar 15;49(6):839-45.

PMID:
7702642
44.

Comparison of mechanical deformation properties of metallic stents with use of stress-strain analysis.

Lossef SV, Lutz RJ, Mundorf J, Barth KH.

J Vasc Interv Radiol. 1994 Mar-Apr;5(2):341-9.

PMID:
8186605
45.

Ras (CXXX) and Rab (CC/CXC) prenylation signal sequences are unique and functionally distinct.

Khosravi-Far R, Clark GJ, Abe K, Cox AD, McLain T, Lutz RJ, Sinensky M, Der CJ.

J Biol Chem. 1992 Dec 5;267(34):24363-8.

46.

Injection characteristics and downstream contrast material distribution of flush aortography catheters: in vitro study.

Froelich J, Barth KH, Lutz RJ, Lossef SV, Lindisch D.

J Vasc Interv Radiol. 1992 Nov;3(4):713-8.

PMID:
1446134
47.
48.

Nucleoplasmic localization of prelamin A: implications for prenylation-dependent lamin A assembly into the nuclear lamina.

Lutz RJ, Trujillo MA, Denham KS, Wenger L, Sinensky M.

Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3000-4. Erratum in: Proc Natl Acad Sci U S A 1992 Jun 15;89(12):5699.

49.

Evaluation of hepatic artery infusion chemotherapy with a procedure they term arterial angiocomputed tomography.

Miller DL, Lutz RJ.

Cancer Invest. 1992;10(2):187-8. No abstract available.

PMID:
1551028
50.

The prenylation of proteins.

Sinensky M, Lutz RJ.

Bioessays. 1992 Jan;14(1):25-31. Review.

PMID:
1546978

Supplemental Content

Support Center